Department of Urology, The Second Hospital of Lanzhou University Medical School, Lanzhou, Gansu, China.
Department of Urology, Nanchong Central Hospital, The Second Clinical College, North Sichuan Medical College (University), Nanchong, China.
Ann Surg Oncol. 2023 Jun;30(6):3805-3816. doi: 10.1245/s10434-023-13221-z. Epub 2023 Mar 6.
For medical institutions without robotic equipment, it remains uncertain whether laparoscopic radical nephroureterectomy (LNU) can achieve results similar to those of robotic surgery for the treatment of upper tract urothelial carcinoma (UTUC). This meta-analysis aimed to compare the efficacy and safety of robot-assisted radical nephroureterectomy (RANU) with that of LNU using a large sample size of patients.
A systematic meta-analysis was performed using data (available to May 2022) acquired from multiple scientific databases. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Assessing the Methodological Quality of Systematic Reviews (AMSTAR) guidelines, according to the protocols registered with PROSPERO (CRD42021264046), were followed to perform this cumulative analysis.
Nine high-quality studies were included in this analysis, considering factors such as operative time (OT), estimated blood loss (EBL), length of hospital stay (LOS), positive surgical margins (PSM), and complications. Statistical indicators revealed no significant differences between the RANU and LNU groups in terms of OT (weighted mean difference [WMD] 29.41, 95% confidence interval [CI] -1.10 to 59.92; p = 0.22), EBL (WMD -55.30, 95% CI -171.14 to 60.54; p = 0.13), LOS (WMD -0.39, 95% CI -1.03 to 0.25; p = 0.12), PSM (odds ratio [OR] 1.22, 95% CI 0.44-3.36; p = 0.17], or complications (OR 0.91, 95% CI 0.49-1.69; p = 0.13).
The meta-analysis showed that the perioperative and safety indicators of both RANU and LNU were similar and both showed favorable outcomes in UTUC treatment. However, some uncertainties remain in the implementation and selection of lymph nodes for dissection.
对于没有机器人设备的医疗机构,腹腔镜根治性肾输尿管切除术(LNU)是否能达到机器人手术治疗上尿路上皮癌(UTUC)的效果仍不确定。本荟萃分析旨在使用大量患者数据比较机器人辅助根治性肾输尿管切除术(RANU)和 LNU 的疗效和安全性。
对 2022 年 5 月前从多个科学数据库中获取的数据进行系统的荟萃分析。按照 PROSPERO(CRD42021264046)注册方案,根据《系统评价和荟萃分析的首选报告项目》(PRISMA)和《系统评价方法学质量评估》(AMSTAR)指南进行荟萃分析。
纳入了 9 项高质量的研究,考虑了手术时间(OT)、估计出血量(EBL)、住院时间(LOS)、切缘阳性(PSM)和并发症等因素。统计学指标显示,RANU 组和 LNU 组在 OT(加权均数差 [WMD] 29.41,95%置信区间 [CI] -1.10 至 59.92;p=0.22)、EBL(WMD -55.30,95% CI -171.14 至 60.54;p=0.13)、LOS(WMD -0.39,95% CI -1.03 至 0.25;p=0.12)、PSM(比值比 [OR] 1.22,95% CI 0.44-3.36;p=0.17)或并发症(OR 0.91,95% CI 0.49-1.69;p=0.13)方面无显著差异。
荟萃分析表明,RANU 和 LNU 的围手术期和安全性指标相似,两者在治疗 UTUC 方面均有良好的效果。然而,在淋巴结清扫的实施和选择方面仍存在一些不确定性。